Brain-penetrant OLIG2 inhibitor CT-179 shows preclinical promise against glioblastoma
Start here
A preprint posted on bioRxiv on 21 October 2026 reports that CT-179, a brain-penetrant small-molecule inhibitor of the transcription factor OLIG2, disrupts mitotic progression in glioblastoma cells and enhances the effectiveness of standard-of-care chemoradiotherapy in preclinical models. In vitro, CT-179 inhibited proliferation across all 11 patient-derived glioblastoma cell lines tested, with IC50 values below 360 nM. Treated cells died by apoptosis arising through mitotic catastrophe, mitotic slippage, or a hybrid of the two responses. The work has not yet been peer reviewed, and no clinical data in patients are available, so translation of the combination approach into human trials remains open.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- bioRxivPickPharmacologic inhibition of OLIG2 by CT-179 disrupts mitotic progression and enhances standard-of-care chemoradiotherapy in glioblastoma
CT-179 is a brain-penetrant small-molecule OLIG2 inhibitor that suppressed proliferation in all 11 patient-derived GBM cell lines (IC50 < 360 nM) and induced apoptosis through mitotic catastrophe, mitotic slippage, or a hybrid response.
Coverage and heat for this story
Reports so far 1·Heat now 4·Peak heat 10 (Oct 20 08:00)·Reports, 24h 0
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.